Related Experiment Video
Updated: Mar 6, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma
Yiliang Bi1, Wei Shen1, Min Min1
1Department of Gastroenterology, 307 Hospital of PLA, Academy of Military Medical Science, Beijing 100071, P.R. China.
Abstract:
Interleukin enhancer binding factor 2 (ILF2) has been found to be markedly upregulated in pancreatic carcinoma and is involved in the pathogenesis of pancreatic carcinoma. Thus, ILF2 may be a potential target for therapy. Yet, the regulatory mechanisms of ILF2 in pancreatic carcinoma remain largely elusive. In the present study, we demonstrated that ILF2 functioned as an oncogene and regulated epithelial-mesenchymal transition (EMT)-associated genes in pancreatic carcinoma PANC-1 cells. MicroRNA-7 (miR-7) suppressed ILF2 mRNA expression and the protein level in PANC-1 cells. Contrary to ILF2, miRNA-7 functioned as a tumor-suppressor gene and negatively regulated EMT-associated genes in the PANC-1 cells. Curcumin, a polyphenol natural product isolated from the rhizome of the plant Curcuma longa, has emerged as a promising anticancer therapeutic agent. We found that treatment with curcumin increased miR-7 expression and suppressed ILF2 protein in the PANC-1 cells. Thus, we identified ILF2 as a new downstream target gene of curcumin. The results revealed that ILF2 is regulated by miR-7 and suggest that downregulation of miR-7 may be an important factor for the ILF2 overexpression in pancreatic carcinoma.
Insights
Interleukin enhancer binding factor 2 (ILF2) acts as an oncogene in pancreatic cancer, driving epithelial-mesenchymal transition. MicroRNA-7 suppresses ILF2, and curcumin treatment boosts miR-7, inhibiting ILF2 and offering therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Interleukin enhancer binding factor 2 (ILF2) is upregulated in pancreatic carcinoma and implicated in its pathogenesis.
- The regulatory mechanisms of ILF2 in pancreatic cancer are not well understood.
- ILF2 may represent a potential therapeutic target for pancreatic cancer.
Purpose of the Study:
- To investigate the role of ILF2 in pancreatic carcinoma PANC-1 cells.
- To explore the regulatory relationship between ILF2, microRNA-7 (miR-7), and epithelial-mesenchymal transition (EMT).
- To assess the effect of curcumin on ILF2 and miR-7 expression in pancreatic cancer cells.
Main Methods:
- Cell culture of pancreatic carcinoma PANC-1 cells.
- Analysis of ILF2 gene and protein expression.
- Investigation of miR-7's regulatory effect on ILF2.
- Assessment of EMT-associated gene regulation by ILF2 and miR-7.
- Treatment of cells with curcumin and evaluation of its impact on miR-7 and ILF2 levels.
Main Results:
- ILF2 functions as an oncogene in PANC-1 cells, regulating EMT-associated genes.
- miR-7 suppresses ILF2 mRNA and protein expression in PANC-1 cells.
- miR-7 acts as a tumor suppressor, negatively regulating EMT-associated genes.
- Curcumin treatment increases miR-7 expression and decreases ILF2 protein levels.
- ILF2 is identified as a downstream target of curcumin.
Conclusions:
- ILF2 is regulated by miR-7 in pancreatic carcinoma.
- Downregulation of miR-7 may contribute to ILF2 overexpression in pancreatic cancer.
- Curcumin demonstrates potential therapeutic value by modulating the miR-7/ILF2 axis and inhibiting EMT.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
Experimental RNAi
lncRNA - Long Non-coding RNAs
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

